Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

Angela Gueli, MD, Marco Ruella, MD, Alessandra Risso, PhD, Tiziana Spatola, PhD, Hui Jing Hu, MD, Daniela Gottardi, MD, Alberto De Crescenzo, MD, Stefano Buttiglieri, PhD, Corrado Tarella, MD

Blood (2011) 118 (21): 1620.

https://doi.org/10.1182/blood.V118.21.1620.1620

Published: 2011

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Marco Ruella, MD, Rosalba Miceli, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Silvia Locatelli, PhD, Arianna Giacomini, PhD, Michele Magni, MD, Paola Matteucci, MD, Stefano Buttiglieri, PhD, Alessandra Risso, PhD, Luigi Mariani, MD, Roberto Passera, PhD, Massimo Di Nicola, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 1289.

https://doi.org/10.1182/blood.V116.21.1289.1289

Published: 2010

Journal Articles

Exposure of Cultured Human Mesenchymal Stem Cells to Chemotherapy Induces An Early and Permanent Telomere Loss: Biological and Clinical Implications

Stefano Buttiglieri, PhD, Tiziana Spatola, PhD, Marco Ruella, MD, Alessandra Risso, PhD, Melissa Montanini, PhD, Silvia Tracchi, PhD, Lorenzo Silengo, MD, Enrico Avvedimanto, MD, Corrado Tarella, MD

Blood (2010) 116 (21): 4776.

https://doi.org/10.1182/blood.V116.21.4776.4776

Published: 2010

Journal Articles

Pre-Operative Bone Marrow-Derived Cell Mobilization by G-CSF Enhances Osseointegration of Bone Substitute In Patients Undergoing Surgery with High Tibial Valgus Osteotomy

Antongiulio Marmotti, MD, Castoldi Filippo, MD, Rossi Roberto, MD, Alessia Tron, MD, Francesco Giacalone, MD, Stefano Marenco, MD, Cristina Realmuto, PhD, Alessandra Risso, PhD, Marco Ruella, MD, Alda Borrè, MD, Paolo Rossi, MD, Corrado Tarella, MD

Blood (2010) 116 (21): 4773.

https://doi.org/10.1182/blood.V116.21.4773.4773

Published: 2010

Journal Articles

Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea

Marco Ruella, MD, Silvia Salmoiraghi, PhD, Alessandra Risso, PhD, Alessandra Carobbio, PhD, Piera Sivera, MD, Irene Ricca, MD, Tiziano Barbui, MD, Corrado Tarella, Alessandro Rambaldi, MD

Blood (2010) 116 (21): 1975.

https://doi.org/10.1182/blood.V116.21.1975.1975

Published: 2010

Journal Articles

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Blood (2008) 112 (11): 3183.

https://doi.org/10.1182/blood.V112.11.3183.3183

Published: 2008

Journal Articles

Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Alberto Rocci, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Adele Testi, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Paola Matteucci, MD, Alessandra Risso, PhD, Marco Ruella, MD, Corrado Tarella, MD, Alesandro M. Gianni, MD

Blood (2008) 112 (11): 2158.

https://doi.org/10.1182/blood.V112.11.2158.2158

Published: 2008

NARROW

Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Exposure of Cultured Human Mesenchymal Stem Cells to Chemotherapy Induces An Early and Permanent Telomere Loss: Biological and Clinical Implications

Pre-Operative Bone Marrow-Derived Cell Mobilization by G-CSF Enhances Osseointegration of Bone Substitute In Patients Undergoing Surgery with High Tibial Valgus Osteotomy

Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.

Email alerts

ASH Publications

American Society of Hematology

Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Exposure of Cultured Human Mesenchymal Stem Cells to Chemotherapy Induces An Early and Permanent Telomere Loss: Biological and Clinical Implications

Pre-Operative Bone Marrow-Derived Cell Mobilization by G-CSF Enhances Osseointegration of Bone Substitute In Patients Undergoing Surgery with High Tibial Valgus Osteotomy

Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only